Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus - Wikidata - thesis-toulmin - TriplyDB

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

http://www.wikidata.org/entity/Q27680499

about

Inhibitory antibodies targeting emerging viruses: advancements and mechanisms Determinants of early life immune responses to RSV infection Stable long-term cultures of self-renewing B cells and their applications Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens Emerging Vaccine Technologies Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments Vaccines for the 21st century Designing vaccines for the twenty-first century society CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Recognition determinants of broadly neutralizing human antibodies against dengue viruses A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present Delivering vaccines to the people who need them most Protein Crystallography in Vaccine Research and Development Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance What Are the Most Powerful Immunogen Design Vaccine Strategies?Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Fine Epitope Mapping of Two Antibodies Neutralizing the Bordetella Adenylate Cyclase Toxin.Challenges and opportunities in developing respiratory syncytial virus therapeutics The Bordetella adenylate cyclase repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies.Pre-fusion structure of a human coronavirus spike protein.Vaccines, new opportunities for a new society.Current views on the potential for development of a HIV vaccine.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing.Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Mucosal vaccines against respiratory syncytial virus Early-life viral infections and the development of asthma: a target for asthma prevention?Transplanting supersites of HIV-1 vulnerability.Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.Asthma: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases

P2860

Q24289645-0C0C8AA8-BF10-46D9-9640-76E4008E8AB6 Q26764790-D04519D9-AF91-4DAB-A090-FD6E61C6A3F0 Q26766723-BEBDCF86-5238-4700-A312-4C6653E61BC2 Q26772129-BD9F1C0F-6309-464B-AE3F-FF091FC3A962 Q26775152-8FA40F58-9DC1-46FA-AD23-8FABE219A2C5 Q26777382-7A41A339-6AD4-495C-909F-ED05A8651CCB Q26783764-20CE7B80-23ED-42B0-93C3-D84CD324AF8A Q26830726-D8937B9C-646F-4391-A19D-264480910622 Q27007529-EDA55E98-9E42-47B0-9689-DD48B9D54FCE Q27025703-88D48A75-9B9D-4780-8529-3DA49894DD98 Q27303940-FEF61FDB-CEC2-4362-B564-E8EAF28C4431 Q27305097-74F0A36F-C08C-49EB-AB2E-CBE161C04777 Q27333522-28299120-9DEB-4A7F-967E-502E903DE065 Q27644383-4E1C21BE-014B-4083-BD47-5198FC36ABF4 Q27697333-4AE36522-0F5B-48D2-A452-80936E080746 Q27701889-7349FC87-82A8-42BE-82C6-16A004245145 Q28075274-A4861F7F-8185-4777-B534-C3FE9C19E73A Q28080556-85A51A62-5EB9-4FAA-A4DC-F7397FB94B30 Q28082744-75D97FF4-9F20-43AC-AFF0-82419F0DE07B Q28087528-A28644E5-0BFE-4BC1-AB82-68F2CF31F99C Q28552909-2988B43E-4A58-4626-9D28-E1215A6B5364 Q28729792-F8AAF10D-040A-4B1E-AC8F-55E2CC920C7B Q30240274-AAC0B445-6E5D-4A64-B694-7870B3ADF377 Q30274818-F8A0AD00-7183-44A1-9988-1E6BF07BFA52 Q30300567-DB304F81-C15A-402F-8658-80FC5B579866 Q30301113-40FBA048-78AB-4917-9610-F9B4E3582524 Q30385177-E818F559-9289-424F-AFA3-F70C556C93DE Q30390904-32238724-DB04-4599-95B5-D45D1D67F656 Q30397595-0BCEC063-FACF-4DF8-9471-9FA4739F9804 Q30490942-01263B72-6E6D-447B-AF48-CA894D0FC7CB Q30657338-25EB0876-0C80-4918-82A7-04B5518FD165 Q30677297-71035975-8774-4537-9AFB-1633FF0EBF30 Q33596700-A491AD1F-B91F-464F-99A8-E75CA7EDF4DA Q33775790-5AD4C816-5D1A-4B8D-B330-2172F8488D09 Q33821896-E315987F-B791-4F25-A1F0-7B600740B992 Q33837530-65527A8D-5401-4451-8E40-E4A085B20A9E Q33852785-9D31660A-7EE5-42DD-8531-C8DA0EB00F67 Q33854841-73100AC6-F22F-4B2A-BF4B-4E223752EED8 Q33887642-B707F223-7029-491F-9F46-EBB5118A243A Q33956813-8613D53F-2C33-43ED-AB6A-05F69B2CB1C5

P2860

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

http://www.wikidata.org/entity/Q27680499

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@ast

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@en

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@nl

type

label

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@ast

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@en

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@nl

prefLabel

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@ast

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@en

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

@nl

P1433

Q27680499-D4558DD4-4C92-4B41-B6A0-4B5435E7354C

P1476

Q27680499-D11D9B4A-AE4D-4CF4-900C-6608CF9AC6B2

P2093

Q27680499-0B961E1E-CB5D-4AC5-9305-1A3D4F3E6AE5

Q27680499-0DC02276-62A1-4CF2-BEE4-6CD5589D4465

Q27680499-1D42CEB1-92F8-4C73-A335-3EA3AA708546

Q27680499-2A7F6578-0E50-4746-B000-2EF5123C36EC

Q27680499-4558F649-BEEB-4B31-AD6F-1D7F529E86A2

Q27680499-4DA8F1A6-1067-46DB-B8DD-3DC2C2884932

Q27680499-4FBB0F70-D5B9-45EA-8305-6D60817AD867

Q27680499-52EB2911-E7BB-4541-B2FC-27F61E3C759D

Q27680499-531E61BF-9B82-454F-815B-9C1733D06D46

Q27680499-5F371FB5-5E38-4A84-90A7-AEAA3ED5FA55

P2860

Q27680499-023FF95A-10D3-4916-A187-A6657971F949

Q27680499-18422657-E406-4BFF-85A4-D859CE295CD8

Q27680499-2120B41B-B9CC-4CB6-8B62-F42CD24C51F3

Q27680499-31FD7172-59F0-44E0-AC7D-E10A30654133

Q27680499-34C07A33-DB2F-467D-8DA3-6C49CAF42D33

Q27680499-39643C98-99B2-40A5-9F04-29FA90697214

Q27680499-4B9AAB4A-DADC-4FF6-A904-4E819EAE831D

Q27680499-4D342EBE-A750-4FE1-B689-6655BD285957

Q27680499-4EFBE11C-7448-4E25-856B-26C65875E265

Q27680499-5235707C-9F21-4C38-9CA6-825D70438965

P304

Q27680499-13A6C3DD-79EF-4C56-A06C-1A7095A915EA

P31

Q27680499-D01F84D6-B264-4100-A59F-95E661DC3CB9

P3181

Q27680499-A28CFDCA-8261-445F-A38C-A601EF1E6219

P356

Q27680499-51744810-5095-44B5-9DCB-1871C7A92E8A

P407

Q27680499-39323540-AC0E-4275-AA09-166C19D005DE

P433

Q27680499-AC2A068A-B749-4A32-9B0E-AC5750330A42

P478

Q27680499-4B078D23-FC1A-4984-AF7C-E072C00DF866

P50

Q27680499-05EEA38D-185C-4124-B4B6-34F37103BBAC

Q27680499-2D35907F-482A-4FFC-8E67-792DC27FC096

Q27680499-40B8016E-D8A9-4FD2-9605-CD86501CE6DA

Q27680499-72FBA4E5-7E55-4048-831C-DB1909EBAE98

Q27680499-8695E928-5EB2-4EEF-AD8A-DF2A768618A6

P577

Q27680499-27DD9FB3-4A9F-4D26-BCF1-71AAE4392E92

P5875

Q27680499-3457175A-6CB8-4582-8413-F37361242323

P698

Q27680499-FABB3442-F47D-4881-A5CB-DE33E90BD713

P921

Q27680499-94E694EA-EE75-48A0-8F05-2A5C36F13C02

Q27680499-AE56A4C6-C8CA-4833-BA32-F79B91173514

P932

Q27680499-403198D8-25E1-4048-90A9-5306B90A3FBF

P3181

P356

SCIENCE.1243283

P1433

P1476

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus

@en

P2093

Anqi Zheng

http://www.w3.org/2001/XMLSchema#string

Arjen Q Bakker

http://www.w3.org/2001/XMLSchema#string

Azad Kumar

http://www.w3.org/2001/XMLSchema#string

Baoshan Zhang

http://www.w3.org/2001/XMLSchema#string

Guillaume B E Stewart-Jones

http://www.w3.org/2001/XMLSchema#string

Gwo-Yu Chuang

http://www.w3.org/2001/XMLSchema#string

Hergen Spits

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Boyington

http://www.w3.org/2001/XMLSchema#string

John-Paul Todd

http://www.w3.org/2001/XMLSchema#string

Kevin W Graepel

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Structural definition of a conserved neutralization epitope on HIV-1 gp120

Processing of X-ray diffraction data collected in oscillation mode

Collagen stabilization at atomic level: crystal structure of designed (GlyProPro)10foldon

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Structural basis of respiratory syncytial virus neutralization by motavizumab

Elicitation of structure-specific antibodies by epitope scaffolds

Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

P304

592-598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1284975

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1243283

http://www.w3.org/2001/XMLSchema#string

P407

P433

6158

http://www.w3.org/2001/XMLSchema#string

P478

342

http://www.w3.org/2001/XMLSchema#string

P50

Syed Mohammad Moin

Jason S McLellan

Barney S. Graham

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258215951

http://www.w3.org/2001/XMLSchema#string

P698

24179220

http://www.w3.org/2001/XMLSchema#string

P921

membrane fusion involved in viral entry into host cell

virus structure

P932

4461862

http://www.w3.org/2001/XMLSchema#string